Genocea Biosciences Inc (GNCA)

4.27
NASDAQ : Health Care
Prev Close 4.27
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.56 / 8.07
Avg Volume 349.40K
Exchange NASDAQ
Shares Outstanding 28.38M
Market Cap 117.22M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RSI Alert: Genocea Biosciences (GNCA) Now Oversold

RSI Alert: Genocea Biosciences (GNCA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genocea Congratulates Jessica Baker Flechtner, Ph.D. For Recognition On 2016's 40 Women To Watch Over 40 List

Genocea Congratulates Jessica Baker Flechtner, Ph.D. For Recognition On 2016's 40 Women To Watch Over 40 List

Genocea Chief Scientific Officer honored for innovation in development of novel immunotherapies

Genocea Reports Second Quarter 2016 Financial Results

Genocea Reports Second Quarter 2016 Financial Results

- GEN-003 Phase 2b Viral Shedding Data Expected in September 2016 -

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a weak on high relative volume candidate

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

6 Breakout Stocks Under $10 Set to Soar

6 Breakout Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient

Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient

Genocea director recognized for outstanding contributions to immunology and infectious disease research through vaccine development

Today's Dead Cat Bounce Stock: Genocea Biosciences (GNCA)

Today's Dead Cat Bounce Stock: Genocea Biosciences (GNCA)

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a weak on high relative volume candidate

Strong On High Relative Volume: Genocea Biosciences (GNCA)

Strong On High Relative Volume: Genocea Biosciences (GNCA)

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a strong on high relative volume candidate

Trade-Ideas: Genocea Biosciences (GNCA) Is Today's

Trade-Ideas: Genocea Biosciences (GNCA) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Genocea Biosciences (GNCA) In A Perilous Reversal

Genocea Biosciences (GNCA) In A Perilous Reversal

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a "perilous reversal" (up big yesterday but down big today) candidate

Genocea Biosciences (GNCA) Stock Soars on Positive Trial Results

Genocea Biosciences (GNCA) Stock Soars on Positive Trial Results

Genocea Biosciences (GNCA) stock is surging on Thursday after the company reported positive efficacy data from a Phase 2 trial for its genital herpes treatment.